Get the Stockscreener App
96.95
1.65%
1.57
After Hours:
96.95
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $96.95, with a volume of 942.85K.
It is up +1.65% in the last 24 hours and up +2.83% over the past month.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
See More
Previous Close:
$95.38
Open:
$95.16
24h Volume:
942.85K
Relative Volume:
0.80
Market Cap:
$10.82B
Revenue:
$2.90B
Net Income/Loss:
$239.11M
P/E Ratio:
45.92
EPS:
2.1112
Net Cash Flow:
$492.45M
1W Performance:
+3.17%
1M Performance:
+2.83%
6M Performance:
-1.34%
1Y Performance:
+7.15%
1-Day Range:
$94.71
$97.01
1-Week Range:
$92.97
$97.26
52-Week Range:
$81.22
$118.30
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
96.95 | 10.64B | 2.90B | 239.11M | 492.45M | 2.1112 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-25 | Initiated | Goldman | Neutral |
| Oct-16-25 | Initiated | Guggenheim | Neutral |
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Revvity stock: Analyst estimates & ratings - MSN
Revvity stock (US76155R1086): cancer test launch and steady demand keep diagnostics group in focus - AD HOC NEWS
Revvity declares $0.07 dividend - MSN
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity Stock: Analyst Estimates & Ratings - inkl
Revvity stock (US76155R1086): diagnostics specialist in focus after latest earnings and life-science - AD HOC NEWS
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity Inc. stock (US76155R1086): investors weigh latest earnings and diagnostics focus - AD HOC NEWS
There May Be Some Bright Spots In Revvity's (NYSE:RVTY) Earnings - 富途牛牛
Revvity's (NYSE:RVTY) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
Revvity stock (US76155R1086): Q1 earnings beat and guidance set the tone - AD HOC NEWS
Revvity (RVTY) Is Down 5.0% After Raising 2026 Outlook And Securing FDA Assay Clearance - Sahm
Revvity stock (US76155R1086): FDA assay clearance, outlook to 2026 and fresh collaboration momentum - AD HOC NEWS
Can Revvity Expand Diagnostics Across the S&P 500 Index? - Kalkine Media
Revvity, Inc. (RVTY): Investor Outlook Reveals 20.94% Potential Upside In Healthcare Innovation - DirectorsTalk Interviews
Revvity stock (US76155R1086): steady diagnostics player after latest quarterly update - AD HOC NEWS
RVTY expands endocrine diagnostics with FDA-cleared testosterone assay - MSN
Revvity stock (US76155R1086): collaboration momentum and diagnostics focus after recent share move - AD HOC NEWS
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Revvity stock (US76155R1086): T. Rowe Price reports a 9% stake - AD HOC NEWS
FDA OKs Revvity’s Total Testosterone Assay - Medical Product Outsourcing
T. Rowe Price (RVTY) discloses 10.1M-share, 9.0% stake in Revvity - Stock Titan
(RVTY) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
The Top 5 Analyst Questions From Revvity’s Q1 Earnings Call - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY) - The Globe and Mail
Revvity stock (US76155R1086): Q1 earnings beat with $1.06 EPS - AD HOC NEWS
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay - The Globe and Mail
BofA Securities Maintains Revvity(RVTY.US) With Hold Rating - Moomoo
Is Revvity stock underperforming the S&P 500? - MSN
Is Revvity Inc (RVTY) a Bargain After 4.3% Drop? GF Value Says U - GuruFocus
Is Revvity Inc (RVTY) a Bargain After 4.3% Drop? GF Value Says Undervalued - GuruFocus
Revvity stock (US76155R1086): FDA clearance for testosterone assay, Q1 earnings beat - AD HOC NEWS
Transcript : Revvity, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 09 - marketscreener.com
FDA Clears Revvity Total Testosterone Assay for Automated Testing - Clinical Lab Products
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution - Yahoo Finance
Revvity (RVTY) grows Q1 2026 sales to $711M while margins tighten - Stock Titan
Revvity stock (US76155R1086): Q1 earnings beat and analyst upgrade drive gains - AD HOC NEWS
Revvity (NYSE:RVTY) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity (RVTY) director Alexis Michas receives stock awards and reports indirect holdings - Stock Titan
REVVITY (RVTY) director granted new restricted stock unit awards - Stock Titan
Revvity (RVTY) director Michael Klobuchar receives new restricted stock unit grants - Stock Titan
Revvity (RVTY) director Frank Witney granted restricted stock unit awards - Stock Titan
Director Samuel R. Chapin receives stock awards at REVVITY (RVTY) with RSUs vesting in 2027 - Stock Titan
Revvity (RVTY) director Michel Vounatsos receives new restricted stock units - Stock Titan
Revvity (RVTY) director Michelle McMurry-Heath granted new RSU awards - Stock Titan
Equity grants add 2,280 shares to Revvity (RVTY) director’s stake - Stock Titan
Revvity (RVTY) Q1 2026 Earnings Transcript - AOL.com
Revvity stock (US76155R1086): Q1 beat and analyst upgrade spark gains - AD HOC NEWS
Mitsubishi UFJ Asset Management Co. Ltd. Trims Stake in Revvity Inc. $RVTY - MarketBeat
Revvity earnings: What to look for from RVTY - MSN
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):